Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
A one-shot gene-editing cholesterol therapy could soon be a reality
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Clears major obesity endpoints at 80 weeks
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
Subscribe To Our Newsletter & Stay Updated
